Clinical Trial

A Randomized Controlled Trial of Spermidine for the Prevention of Radiation-Induced Xerostomia in Head and Neck Squamous Cell Carcinoma (Including Nasopharyngeal Carcinoma)

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Record status
This record was last updated June 26, 2025 (before its estimated June 8, 2026 completion). Its status may not reflect the trial's current state.
Summary
This study is a single-center, double-blind, randomized controlled clinical trial with placebo as the control, aiming to evaluate the effectiveness of spermidine in preventing radiation-induced xerostomia during radiotherapy for head and neck tumors (including nasopharyngeal carcinoma).
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-06-24.
Status change: Not Yet Recruiting → Recruiting 2025-06-24
Trial Details
NCT Number NCT07035626
Lead Sponsor West China Hospital
Conditions Radiation-induced Xerostomia
Enrollment 58 participants
Start Date 2025-06-25
Primary Completion 2026-06-08 (estimated)
Study Completion 2026-06-08 (estimated)
Updated on ClinicalTrials.gov 2025-06-26